Pratik Srivastava

“Sir, I just wanted to understand the share and the economics a little better. I see that in the deck you mentioned, it's a, you know, USD 1.25 million, 12.15 million contract.”

“First of all, again, congratulations, sir, on the great numbers, and I definitely like your question. Oh, a few questions which I had.”

“Sir, my question, again, is, you know, more broader, but beyond safety recall, you know, or 7ACA, what are, like, the 5-6 target, you know, products that are probably furthest along in the filing and approval process, sir?”

“So, first of all, congratulations to the management on doing a fantastic job of turning the company around and improving the financial. Sir, my question is, my first question actually is on the, maybe I missed it when you were probably earlier describing.”

“First of all, congratulations for a great set of numbers. My first question is on the API oncology side of things, sir. So we have this new oncology block expansion, which is underway, and it's ready to be completed by FI 27 for around 15 plus new oncology APIs, right?”